{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:14:15Z","timestamp":1791828855263,"version":"4.3.4"},"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Janus kinase inhibitors (JAKinibs) are increasingly used for autoimmune diseases, prompting concerns about their cardiovascular safety. This study aims to assess the cardiovascular safety of JAKinibs in real-world settings. We conducted a retrospective analysis of FDA Adverse Event Reporting System (FAERS) data from the fourth quarter of 2012 to the second quarter of 2023, focusing on cardiovascular adverse events (AEs) associated with JAKinibs. We used disproportionality analysis to calculate reporting odds ratios (RORs) and identify signals of increased cardiovascular risk. This study identified 13,556 reports of cardiovascular AEs associated with JAKinibs in the FAERS database. Compared to the full database, Baricitinib exhibited significant signals for embolic and thrombotic events (ROR<jats:sub>025<\/jats:sub>\u2009=\u20095.58), ischemic heart disease (ROR<jats:sub>025<\/jats:sub>\u2009=\u20091.56), and cardiac arrhythmias (ROR<jats:sub>025<\/jats:sub>\u2009=\u20091.14). Tofacitinib was associated with the signal for hypertension (ROR<jats:sub>025<\/jats:sub>\u2009=\u20091.05), and upadacitinib was linked to embolic and thrombotic events (ROR<jats:sub>025<\/jats:sub>\u2009=\u20091.23). When compared to TNF-\u03b1 inhibitors, upadacitinib, baricitinib and tofacitinib showed 7, 6, and 2 positive signals, respectively (all ROR<jats:sub>025<\/jats:sub>\u2009&gt;\u20091). These findings highlight the need for careful cardiovascular monitoring and risk assessment for patients receiving JAKinibs, particularly those with pre-existing cardiovascular risk factors or older age.<\/jats:p>","DOI":"10.1371\/journal.pone.0322849","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T18:00:16Z","timestamp":1747072816000},"page":"e0322849","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":13,"title":["Cardiovascular safety of Janus kinase inhibitors: A pharmacovigilance study from 2012\u20132023"],"prefix":"10.1371","volume":"20","author":[{"given":"Xiaoyan","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianchun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuexi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shurong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8672-0874","authenticated-orcid":true,"given":"Yilan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,5,12]]},"reference":[{"issue":"2","key":"pone.0322849.ref001","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41584-023-01062-9","article-title":"Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician","volume":"20","author":"Z Szekanecz","year":"2024","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"pone.0322849.ref002","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","article-title":"JAK inhibitors in dermatology: The promise of a new drug class","volume":"76","author":"W Damsky","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"pone.0322849.ref003"},{"key":"pone.0322849.ref004"},{"key":"pone.0322849.ref005"},{"issue":"2","key":"pone.0322849.ref006","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001595","article-title":"Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37\u2009066 patient-years of tofacitinib exposure","volume":"7","author":"GR Burmester","year":"2021","journal-title":"RMD Open"},{"issue":"4","key":"pone.0322849.ref007","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis","volume":"386","author":"SR Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"pone.0322849.ref008"},{"issue":"7","key":"pone.0322849.ref009","doi-asserted-by":"crossref","first-page":"454","DOI":"10.2174\/0113894501290296240327081624","article-title":"Drug Repurposing Using FDA Adverse Event Reporting System (FAERS) Database","volume":"25","author":"R Morris","year":"2024","journal-title":"Curr Drug Targets"},{"issue":"4","key":"pone.0322849.ref010","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40264-019-00901-7","article-title":"Hypoglycemia Associated with Antibiotics Alone and in Combination with Sulfonylureas and Meglitinides: An Epidemiologic Surveillance Study of the FDA Adverse Event Reporting System (FAERS)","volume":"43","author":"KE Kennedy","year":"2020","journal-title":"Drug Saf"},{"issue":"6","key":"pone.0322849.ref011","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/bjd\/ljad039","article-title":"Increased reporting of cerebrovascular accidents with use of risankizumab observed in the Food and Drug Administration Adverse Events Reporting System (FAERS)","volume":"188","author":"A Egeberg","year":"2023","journal-title":"Br J Dermatol"},{"issue":"1","key":"pone.0322849.ref012","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12916-024-03274-6","article-title":"Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database","volume":"22","author":"J Zhou","year":"2024","journal-title":"BMC Med"},{"issue":"4","key":"pone.0322849.ref013","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1136\/ard-2022-223406","article-title":"Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme","volume":"82","author":"M Dougados","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"pone.0322849.ref014","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/acr2.11232","article-title":"Postapproval Comparative Safety Study of Tofacitinib and Biological Disease-Modifying Antirheumatic Drugs: 5-Year Results from a United States-Based Rheumatoid Arthritis Registry","volume":"3","author":"JM Kremer","year":"2021","journal-title":"ACR Open Rheumatol"},{"issue":"3","key":"pone.0322849.ref015","article-title":"Real-world effectiveness and safety of tofacitinib and abatacept in patients with rheumatoid arthritis","volume":"6","author":"W Hirose","year":"2022","journal-title":"Rheumatol Adv Pract"},{"issue":"11","key":"pone.0322849.ref016","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1111\/1756-185X.14414","article-title":"Comparative safety of Janus kinase inhibitors and tumor necrosis factor inhibitors in patients undergoing treatment for rheumatoid arthritis","volume":"25","author":"Y-F Fang","year":"2022","journal-title":"Int J Rheum Dis"},{"issue":"6","key":"pone.0322849.ref017","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/annrheumdis-2021-221915","article-title":"Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study","volume":"81","author":"F Khosrow-Khavar","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"pone.0322849.ref018","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/jdv.19426","article-title":"The safety of systemic Janus kinase inhibitors in atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials","volume":"38","author":"S Yoon","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"pone.0322849.ref019","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s40264-023-01333-0","article-title":"Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors","volume":"46","author":"V Yang","year":"2023","journal-title":"Drug Saf"},{"issue":"1","key":"pone.0322849.ref020","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/heartjnl-2019-316378","article-title":"Cardiovascular disease risk in immune-mediated inflammatory diseases: recommendations for clinical practice","volume":"108","author":"R Agca","year":"2022","journal-title":"Heart"},{"issue":"1","key":"pone.0322849.ref021","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13075-017-1315-z","article-title":"Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study","volume":"19","author":"K Bengtsson","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"pone.0322849.ref022","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update","volume":"76","author":"R Agca","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"pone.0322849.ref023","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40104-016-0100-1","article-title":"High-concentrate feeding upregulates the expression of inflammation-related genes in the ruminal epithelium of dairy cattle","volume":"7","author":"R Zhang","year":"2016","journal-title":"J Anim Sci Biotechnol"},{"issue":"34","key":"pone.0322849.ref024","doi-asserted-by":"crossref","first-page":"29610","DOI":"10.1074\/jbc.M111.226209","article-title":"Mitochondrial-targeted Signal transducer and activator of transcription 3 (STAT3) protects against ischemia-induced changes in the electron transport chain and the generation of reactive oxygen species","volume":"286","author":"K Szczepanek","year":"2011","journal-title":"J Biol Chem"},{"issue":"2","key":"pone.0322849.ref025","first-page":"118","article-title":"Roles of STATs signaling in cardiovascular diseases","volume":"1","author":"R Kishore","year":"2012","journal-title":"JAKSTAT"},{"issue":"4","key":"pone.0322849.ref026","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.yjmcc.2011.01.002","article-title":"A murine model of inducible, cardiac-specific deletion of STAT3: its use to determine the role of STAT3 in the upregulation of cardioprotective proteins by ischemic preconditioning","volume":"50","author":"R Bolli","year":"2011","journal-title":"J Mol Cell Cardiol"},{"issue":"3","key":"pone.0322849.ref027","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.3892\/mmr.2020.11266","article-title":"Statin rosuvastatin inhibits apoptosis of human coronary artery endothelial cells through upregulation of the JAK2\/STAT3 signaling pathway","volume":"22","author":"K Wang","year":"2020","journal-title":"Mol Med Rep"},{"issue":"1","key":"pone.0322849.ref028","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3899\/jrheum.171361","article-title":"Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment","volume":"46","author":"JS Smolen","year":"2019","journal-title":"J Rheumatol"},{"issue":"2","key":"pone.0322849.ref029","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1136\/annrheumdis-2014-206478","article-title":"Safety and efficacy of baricitinib at 24\u2005weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate","volume":"74","author":"EC Keystone","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"pone.0322849.ref030","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/art.39953","article-title":"Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment","volume":"69","author":"R Fleischmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"pone.0322849.ref031","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2019.04.059","article-title":"Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis","volume":"18","author":"BE Sands","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"19","key":"pone.0322849.ref032","doi-asserted-by":"crossref","first-page":"7390","DOI":"10.3390\/ijms21197390","article-title":"Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis","volume":"21","author":"PJ Kotyla","year":"2020","journal-title":"Int J Mol Sci"},{"key":"pone.0322849.ref033","doi-asserted-by":"crossref","first-page":"906753","DOI":"10.3389\/fcvm.2022.906753","article-title":"Ferroptosis and Autophagy-Related Genes in the Pathogenesis of Ischemic Cardiomyopathy","volume":"9","author":"Y Zheng","year":"2022","journal-title":"Front Cardiovasc Med"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0322849","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T18:00:22Z","timestamp":1747072822000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0322849"}},"subtitle":[],"editor":[{"given":"Yashendra","family":"Sethi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,5,12]]},"references-count":33,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0322849","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,12]]}}}